Ind-Swift Laboratories Ratios

Ind-Swift Laboratories Ltd Ratios

The Ind-Swift Laboratories Ltd Ratios page provides a complete fundamental analysis of Ind-Swift Laboratories Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Ind-Swift Laboratories Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Ind-Swift Laboratories Ltd (NSE: INDSWFTLAB, BSE: 532305) is currently trading at ₹141.51, with a market capitalization of ₹11.57B. As a major player in the Health technology sector and Pharmaceuticals: major industry, Ind-Swift Laboratories Ltd remains a key stock for fundamental analysis using Ind-Swift Laboratories Ltd Ratios.

Ind-Swift Laboratories Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Ind-Swift Laboratories Ltd P/E ratio currently stands at 2.39, making it one of the most tracked metrics in Ind-Swift Laboratories Ltd Ratios.

Historically, the Ind-Swift Laboratories Ltd P/E ratio has shown strong fluctuations:

• 2024: 2.39
• 2023: 1.08
• 2022: 6.86
• 2021: 0
• 2020: 0

The rising Ind-Swift Laboratories Ltd P/E ratio indicates increasing investor confidence and premium valuation.

Price to Book Ratio (P/B)

The Ind-Swift Laboratories Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 0.49.

Historical P/B trend:

• 2024: 0.49
• 2023: 0.72
• 2022: 0.48
• 2021: 0.65

Ind-Swift Laboratories Ltd shows reasonable valuation compared to its asset base.

Price to Sales Ratio (P/S)

The Ind-Swift Laboratories Ltd P/S ratio currently stands at 1.06, an important part of Ind-Swift Laboratories Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 1.06
• 2023: 0.34
• 2022: 0.27
• 2021: 0.38

The rising Ind-Swift Laboratories Ltd P/S ratio indicates improved revenue valuation by investors.

Ind-Swift Laboratories Ltd Price to Cash Flow Ratio (P/CF)

The Ind-Swift Laboratories Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 0.

Historical Ind-Swift Laboratories Ltd Price to Cash Flow Ratio:

• 2024: 0
• 2023: 0
• 2022: 4.66
• 2021: 8.30
• 2020: 7.97

The declining Ind-Swift Laboratories Ltd Price to Cash Flow Ratio suggests improving cash flow strength.

Ind-Swift Laboratories Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Ind-Swift Laboratories Ltd EV currently stands at ₹1.66B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 1.66B
• 2023: 2.94B
• 2022: 11.61B
• 2021: 13.14B

Ind-Swift Laboratories Ltd enterprise value consolidation suggests stable valuation.

EV/EBITDA Ratio

The Ind-Swift Laboratories Ltd EV/EBITDA ratio is currently 0, a key metric in Ind-Swift Laboratories Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 0
• 2023: 0.96
• 2022: 5.03
• 2021: 6.27

Stable Ind-Swift Laboratories Ltd EV/EBITDA indicates balanced valuation.

Ind-Swift Laboratories Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Ind-Swift Laboratories Ltd D/E ratio is currently 0.03, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.03
• 2023: 0.25
• 2022: 1.24
• 2021: 1.56

Ind-Swift Laboratories Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Ind-Swift Laboratories Ltd ROE currently stands at 23.75%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 23.75
• 2023: 71.92
• 2022: 7.38
• 2021: -0.35

Ind-Swift Laboratories Ltd demonstrates strong profitability and efficient capital utilization.

Ind-Swift Laboratories Ltd Ratios Analysis Summary

The Ind-Swift Laboratories Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Ind-Swift Laboratories Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Ind-Swift Laboratories Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.